[Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome].
The influence of angiotensin II blocker in thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome was assessed. 32 patients were treated with eprosartan during 16 weeks. Dynamics of lipid peroxidation in plasma and thrombocytes, liquid part of blood and platelets antioxidant immunity, thrombocytes aggregative capacity were assessed. The results were processed using Student's test. The use of eprosartan in patients with arterial hypertension and metabolic syndrome has positive influence on peroxidation syndrome and optimizes thrombocytes aggregation.
Simonenko
V B
VB
Medvedev
I N
IN
Kumova
T A
TA
D000179:Acrylates / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D000179:Acrylates; D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan